1. Home
  2. SACH vs ICCC Comparison

SACH vs ICCC Comparison

Compare SACH & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sachem Capital Corp.

SACH

Sachem Capital Corp.

HOLD

Current Price

$1.06

Market Cap

50.6M

Sector

Real Estate

ML Signal

HOLD

Logo ImmuCell Corporation

ICCC

ImmuCell Corporation

N/A

Current Price

$6.27

Market Cap

55.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SACH
ICCC
Founded
2010
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.6M
55.5M
IPO Year
2017
1987

Fundamental Metrics

Financial Performance
Metric
SACH
ICCC
Price
$1.06
$6.27
Analyst Decision
Hold
Analyst Count
3
0
Target Price
$2.00
N/A
AVG Volume (30 Days)
141.8K
25.5K
Earning Date
11-05-2025
02-25-2026
Dividend Yield
18.87%
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.26
Revenue
$3,906,000.00
$27,769,304.00
Revenue This Year
N/A
N/A
Revenue Next Year
$1.73
N/A
P/E Ratio
N/A
$24.27
Revenue Growth
N/A
16.49
52 Week Low
$0.80
$4.28
52 Week High
$1.35
$7.60

Technical Indicators

Market Signals
Indicator
SACH
ICCC
Relative Strength Index (RSI) 52.28 52.97
Support Level $1.03 $6.15
Resistance Level $1.07 $6.92
Average True Range (ATR) 0.02 0.33
MACD 0.00 -0.05
Stochastic Oscillator 57.14 31.82

Price Performance

Historical Comparison
SACH
ICCC

About SACH Sachem Capital Corp.

Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.

About ICCC ImmuCell Corporation

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.

Share on Social Networks: